Systemic therapy for non‐small cell lung cancer (NSCLC) has markedly improved patient outcomes, particularly with the advent of molecular‐targeted agents—such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and anaplastic lymphoma kinase (ALK) inhibitors—and immune checkpoint inhibitors (ICIs), in addition to conventional platinum‐based cytotoxic chemotherapy [1, 2, 3]. Here, ALK is linked to lung cancer.